Shionogi

Shionogi, GARDP and CHAI team up to increase antibiotic access worldwide

Shionogi is proud to work on such an innovative licence agreement with GARDP and CHAI to accelerate antibiotic access. ... priorities. Shionogi and GARDP will publish their licence agreement to help create a new baseline for similar deals in the future.

Shionogi Europe and NHS England agree on antibiotic subscription model

Shionogi Europe has entered into an agreement with NHS England to initiate an innovative subscription payment model for the reimbursement of Fetroja (cefiderocol) in England. ... to healthcare systems and society,” said Mark Hill, senior vice president,

Shionogi and F2G partner to develop antifungal treatment olorofim

Shionogi and F2G have partnered to develop and commercialise the new antifungal agent olorofim – formerly F901318 – for invasive fungal infections in Europe and Asia. ... F2G will receive an upfront payment of $100m from Shionogi and share

MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients

RESP-X – in-licensed from Shionogi – is a new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients.

NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan

NHS England, the National Institute for Health and Care Excellence (NICE) and the UK Department of Health have concluded an assessment of Pfizer’s Zavicefta (ceftazidime with avibactam) and Shionogi’s ... Both Pfizer and Shionogi submitted the drugs

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]